by The global viral vectors & plasmid DNA manufacturing market size reached USD 6.26 billion in 2024 and is expected to be surpass around USD 26.66 billion by 2034 with a CAGR of 15.59%.
Get Sample Copy of Report@ https://www.precedenceresearch.com/sample/1012
Key Takeaways
- North America led the market with a 49% revenue share in 2024.
- The AAV segment emerged as the leading vector type in the viral vectors & plasmid DNA manufacturing market, holding a 21% revenue share in 2024.
- The downstream processing segment maintained a dominant position in the workflow category, capturing 54% of the revenue share in 2023.
- The vaccinology segment held the largest share by application, contributing approximately 22.5% of the revenue in 2024.
- The cancer segment was the most dominant by disease type, accounting for 38% of the market revenue in 2024.
- Research institutes were the leading end-use segment, securing around 58.4% of the revenue share in 2024.
Market Overview
The viral vectors and plasmid DNA manufacturing market is rapidly growing, driven by breakthroughs in genetic engineering and therapeutic applications. With gene therapy gaining traction as a treatment for various diseases, the need for high-quality viral vectors and plasmid DNA is increasing. The biopharmaceutical industry’s expansion and technological advancements are key contributors to market growth.
Drivers
The rapid advancements in gene editing technologies, such as CRISPR, are fueling demand for viral vector manufacturing. The rise in rare disease research and cancer gene therapy applications has also increased production needs. Moreover, pharmaceutical companies are investing in scalable and efficient bioprocessing techniques to meet growing global demand.
Opportunities
The expansion of contract manufacturing organizations (CMOs) presents new growth opportunities, enabling biotech firms to scale up production. The increasing application of viral vectors in vaccine development, particularly for infectious diseases, is further boosting market potential. Additionally, the push for automation and AI-driven biomanufacturing solutions is expected to enhance efficiency and reduce costs.
Challenges
One of the primary challenges is the complex and time-consuming production process of viral vectors. Regulatory requirements for safety and efficacy also pose obstacles, as approval timelines can be lengthy. Moreover, the high cost of research and development makes it difficult for smaller biotech firms to enter the market.
Regional Insights
North America remains at the forefront, with strong government support and advanced biotech infrastructure. Europe is making strides in gene therapy innovation, particularly in France and Switzerland. Meanwhile, Asia-Pacific countries like Japan, China, and South Korea are increasing their investments in biotechnology, positioning themselves as emerging leaders in the market.
Viral Vectors & Plasmid DNA Manufacturing Market Companies
- Novasep
- Aldevron
- MerckWaismanBiomanufacturing
- Creative Biogene
- The Cell and Gene Therapy Catapult
- Cobra Biologics
- uniQure N.V.
- Addgene
- FUJIFILM Holdings Corporation
- Oxford Biomedicaplc
- Takara Bio Inc.
Recent Developments
- In May 2024, Charles River Laboratories International, Inc. declared the starting of its Modular and Fast Track viral vector technology transfer frameworks.
- In November 2023, SK Pharmteco Co., South Korean conglomerate SK Group’s contract development and manufacturing organization, has recently started two new viral vector platforms expected to save time and cost in manufacturing innovative cell and gene therapies (CGTs).
- In February 2023, ProBio and RVAC Medicines Pte. Ltd. declared an agreement to establish a strategic partnership to produce GMP-grade plasmid DNA (pDNA) for its mRNA COVID-19 vaccine candidate, RVM-V001, along with collaboration for future therapeutic pipelines.
Market Segmentation
This research report estimates revenue growth at global, regional, and country levels and offers an analysis of present industry trends in everysub-segment from 2025 to 2034. This research study analyzes market thoroughly by classifying global viral vectors & plasmid DNA manufacturing market report on the basis of different parameters including type of vector, application, workflow, end users, disease, and region:
By Vector Type
- Adenovirus
- Plasmid DNA
- Lentivirus
- Retrovirus
- AAV
- Others
By Application
- Gene Therapy
- Antisense &RNAi
- Cell Therapy
- Vaccinology
By Workflow
- Upstream Processing
- Vector Recovery/Harvesting
- Vector Amplification & Expansion
- Downstream Processing
- Fill-finish
- Purification
By End-User
- Biopharmaceutical and Pharmaceutical Companies
- Research Institutes
By Disease
- Genetic Disorders
- Cancer
- Infectious Diseases
- Others
By Geography
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of the World
Ready for more? Dive into the full experience on our website@ https://www.precedenceresearch.com/
